Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.

MUC1 MUC28z CAR T cells TAB004 immunotherapy triple-negative breast cancer

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 12 11 2020
accepted: 13 11 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 29 12 2020
Statut: epublish

Résumé

[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

Identifiants

pubmed: 33365036
doi: 10.3389/fimmu.2020.628776
pmc: PMC7750685
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

628776

Commentaires et corrections

Type : ErratumFor

Informations de copyright

Copyright © 2020 Zhou, Yazdanifar, Roy, Whilding, Gavrill, Maher and Mukherjee.

Auteurs

Ru Zhou (R)

Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States.

Mahboubeh Yazdanifar (M)

Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States.

Lopamudra Das Roy (LD)

Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States.

Lynsey M Whilding (LM)

School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital Campus, London, United Kingdom.

Artemis Gavrill (A)

School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital Campus, London, United Kingdom.

John Maher (J)

School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital Campus, London, United Kingdom.

Pinku Mukherjee (P)

Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, United States.

Classifications MeSH